The pharmaceutical industry has been very optimistic about the potential of 3D printing technology to revolutionize the way we produce and administer drugs. Through the use of additive manufacturing, drugs could be custom tailored to individuals to accommodate different dosages and health needs. However, until now, very little has been done to take advantage of these possibilities.
This is all thanks to Aprecia, a pharmaceutical giant that is investing in a $25 million facility for the production of “ZipDose” products. These products are aimed at creating pills with 3D printers, which promises to be a quicker and more efficient process than any existing drug manufacturing process. Further, the company hopes to be able to create “nano doses” of drugs so as to target illnesses with greater precision.
Though ZipDose has yet to be approved by the FDA, Aprecia has submitted for approval last October and hopes to receive approval soon.
